The Lieber group is focused broadly on nanoscience and nanotechnology, and the interface of these areas with biology and medicine. Central to our vision for the future is the capability to synthesize and illuminate unique physical properties of novel nanoscale materials, and to exploit these structures and other concepts from nanoscience to design powerful new tools for investigating fundamental questions in biology as well as developing novel electronic therapeutics for treatment of human disease. We are committed to realizing this intellectual vision through studies currently focused on three major areas:

  1. Nanomaterials. The synthesis of new nanoscale materials with unique physical properties can enable revolutionary advances in science and technology. The Lieber group is a leader in the design, synthesis, characterization, and hierarchical assembly of nanoscale materials. In addition, the Lieber group focuses on characterizing fundamental physical properties of these materials, and also developing novel nanodevice structures and arrays of devices that are used in studies at the interface with biology and medicine.
  2. Nano-Bioelectronics. Research at the interface between nanoscience and biology has the potential to produce breakthroughs in fundamental science and lead to revolutionary technologies. The Lieber group has played a leading role in defining the fundamental science, engineering and novel technologies at the interface between nanoelectronics and the life sciences, from development of sensors for real-time disease detection, to creating nanoelectronic tools for single cell and subcellular electrophysiology, and the development of novel cyborg cells and hybrid nanoelectronics-innervated tissues.
  3. Brain Science. The Lieber group has a large program focused on a conceptually novel approach for integrating electronics within the brain and other areas of the nervous system, which involves the development of neural network-like mesh electronics and a noninvasive delivery method into targeted distinct brain regions via syringe-injection. We are actively exploiting this new paradigm for tackling fundamental questions in cognitive and behavioral neuroscience, and as powerful new approaches for treatment of neurological and neurodegenerative diseases, traumatic brain and spinal cord injury, and ultimately enhancing human performance via brain-machine interface.